Jozefien Buyze
PhD researcher / statistical author (exact current title not verified)
Data updated
Papers
Trials
Research Footprint
Jozefien Buyze appears in 4 tracked papers (2023–2026), most studied alongside Esketamine and Ketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression (185 citations).
Frequent co-authors: Allan Young, Daniel Fu and Ibrahim Turkoz.
Background & Research
Jozefien Buyze appears as an author on several clinical psychiatry papers from the ESCAPE-TRD program, including randomized comparisons of esketamine nasal spray and quetiapine extended-release for treatment-resistant depression. Publicly indexed records associate the work with Janssen-affiliated research outputs, but a definitive personal faculty profile or full professional biography was not found in the sources reviewed.
Key Impact
A contributing author on multiple ESCAPE-TRD esketamine studies comparing esketamine nasal spray with quetiapine XR/ER in treatment-resistant depression.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →